Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone marrow-derived mesenchymal stromal cells (Mario Negri Institute)
- Development stage
- Unknown
- Lead developer
- Mario Negri Institute for Pharmacological Research
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an experimental cell-based therapy developed by the Mario Negri Institute for Pharmacological Research, consisting of allogeneic, ex vivo-expanded mesenchymal stromal cells (MSCs) derived from bone marrow. The therapy is specifically investigated for the treatment of cisplatin-induced acute kidney injury (AKI) in patients with solid tumors. The mechanism of action involves the cells' ability to migrate to the site of injury and exert paracrine effects, secreting various growth factors and anti-apoptotic signals that facilitate the repair and protection of damaged renal tubular epithelial cells. A Phase 1 clinical trial (NCT01275612) was conducted to evaluate the safety, feasibility, and dose-escalation of a single intravenous infusion of these cells in patients at risk of nephrotoxicity following chemotherapy.
- Other names
- BM-MSCsmesenchymal stem cellsex vivo-expanded donor mesenchymal stem cellsmesenchymal stromal cell-Mario Negri Institute for Pharmacological Research-acute kidney injury
Beyond the preview
Go deeper on bone marrow-derived mesenchymal stromal cells (Mario Negri Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone marrow-derived mesenchymal stromal cells (Mario Negri Institute).